Physician profile
Travis J Keller
NPI 1356394985
$11,028.14
in general payments reported to CMS, 2019-2025
72 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $1,593 · 2021: $1,971 · 2022: $1,625 · 2023: $1,667 · 2024: $1,260 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,076.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,298.97 | 2019-2025 | |
| Pfizer INC. | $1,093.29 | 2019-2025 | |
| Novo Nordisk INC | $1,015.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,014.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $639.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $593.50 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.77 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $292.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $288.98 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Amarin Pharma, INC. | $264.86 | 2019-2021 | |
| Antares Pharma, INC. | $258.99 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Allergan, INC. | $235.42 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $232.97 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $220.08 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $215.04 | 2019-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.